The Cerebellum in Alzheimer's Disease
The DOI matches its Crossref record.
Abstract
The cerebellum is a relatively neglected area of the Alzheimer's disease (AD) brain, probably because it was formerly thought to be spared by the disease. However, a number of pathological changes have now been revealed in the AD cerebellum, principally by immunocytochemical studies, including widespread deposits of diffuse amyloid, ubiquitin-immunoreactive dystrophic neurites, and increased microglia, but tau-immunoreactive neurofibrillary tangles have not been seen. Although the observed changes may be merely epiphenomenal to the pathological processes occurring in the AD neocortex and hippocampus, the morphological and immunocytochemical differences between AD cerebral cortex and cerebellar cortex may nonetheless give insights into the molecular factors involved in the development of the neuropathological lesions of AD brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
“Conversely, τ pathology appears unnecessary for development of brain insulin resistance, because we found such resistance in the cerebellar cortex, where τ (unlike Aβ) pathology is virtually absent in AD (60, 141).”
BackgroundIn Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease
Baron, J. C., Chételat, G., Desgranges, B., Perchey, G., Landeau, B., de la Sayette, V., & Eustache, F. (2001) · NeuroImage · doi:10.1006/nimg.2001.0848 · Cited by 684
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
Evidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507
Microglial activation and amyloid deposition in mild cognitive impairment: A PET study
Okello, A., Edison, P., Archer, H. A., Turkheimer, F. E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338622.27876.0d · Cited by 367
The cerebellum in Alzheimer’s disease: evaluating its role in cognitive decline
Jacobs, H. I. L., Hopkins, D. A., Mayrhofer, H. C., Bruner, E., van Leeuwen, F. W., Raaijmakers, W., & Schmahmann, J. D. (2018) · Brain · doi:10.1093/brain/awx194 · Cited by 338
The Role of the Cerebellum in Cognition and Behavior: A Selective Review
Rapoport, M., van Reekum, R., & Mayberg, H. (2000) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.12.2.193 · Cited by 313
Snowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002266 · Cited by 309
Planel, E., Miyasaka, T., Launey, T., Chui, D.-H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayashi, Y., & Takashima, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5561-03.2004 · Cited by 261
Larner, A. J., & Doran, M. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0019-5 · Cited by 256
Self-citationSultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Markesbery, W. R., Zhou, X. Z., Lu, K. P., & Butterfield, D. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.005 · Cited by 253
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
“We show that the difference in glucose uptake between LMTM monotherapy and add-on therapy is 2–3-fold greater in neocortical regions affected by neurofibrillary degeneration [6–8] than in cerebellum which is not affected [54].”
BackgroundCorrelating familial Alzheimer’s disease gene mutations with clinical phenotype
Ryan, N. S., & Rossor, M. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.92 · Cited by 176
Low density of sigma1 receptors in early Alzheimer’s disease
Mishina, M., Ohyama, M., Ishii, K., Kitamura, S., Kimura, Y., Oda, K.-I., Kawamura, K., Sasaki, T., Kobayashi, S., Katayama, Y., et al. (2008) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0094-z · Cited by 172
Takeda, S., Commins, C., DeVos, S. L., Nobuhara, C. K., Wegmann, S., Roe, A. D., Costantino, I., Fan, Z., Nicholls, S. B., Sherman, A. E., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24716 · Cited by 113
Colombo, G., Cubero, R. J. A., Kanari, L., Venturino, A., Schulz, R., Scolamiero, M., Agerberg, J., Mathys, H., Tsai, L.-H., Chachólski, W., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01167-6 · Cited by 100
Expression of apoptosis related proteins in brains of patients with Alzheimer's disease
Engidawork, E., Gulesserian, T., Seidl, R., Cairns, N., & Lubec, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01618-4 · Cited by 91
Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease
Sepulveda‐Falla, D., Matschke, J., Bernreuther, C., Hagel, C., Puig, B., Villegas, A., Garcia, G., Zea, J., Gomez‐Mancilla, B., Ferrer, I., et al. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00469.x · Cited by 82
“Our data are in agreement with earlier studies showing Ab deposition in the molecular layer of patients with PS1 mutations (28).”
BackgroundResult18 F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease
Nasrallah, I. M., Chen, Y. J., Hsieh, M.-K., Phillips, J. S., Ternes, K., Stockbower, G. E., Sheline, Y., McMillan, C. T., Grossman, M., & Wolk, D. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194282 · Cited by 60
“SUVR were calculated by normalization to mean uptake in cerebellar GM, where NFTs are rare in AD (29).”
MethodThe Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimer’s Disease
Hoxha, E., Lippiello, P., Zurlo, F., Balbo, I., Santamaria, R., Tempia, F., & Miniaci, M. C. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00396 · Cited by 58
“Several studies in AD patients have reported diffuse amyloid plaques in the cerebellum particularly in those with the pre-senile onset of dementia (Larner, 1997).”
BackgroundMa, D., Holmes, H. E., Cardoso, M. J., Modat, M., Harrison, I. F., Powell, N. M., O’Callaghan, J. M., Ismail, O., Johnson, R. A., O’Neill, M. J., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00011 · Cited by 36
“The cerebellum is traditionally considered unaffected in AD, although recent studies have shown increase evidence that it is also affected during the AD disease progression (Larner, 1997; Jacobs et al., 2018), which is also the case for rTg4510 (Xie et al.”
BackgroundDaulatzai, M. A. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9528-x · Cited by 12
“Hence, cerebellar lesions also constitute one of the important neuropathological factors in dementia (Larner 1997; Sjöbeck and Englund 2001; Stępień et al. 2012) causing dysfunctional episodic memory retrieval (McLaren et al.”
Background
Metadata
- Authors
- Larner, A. J.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 1997
- Volume
- 8
- Issue
- 4
- Pages
- 203-209
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2004856335
- Cited by
- 124
- References
- 0
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.